Fresenius SE & Co (FSNUY)
OTHER OTC:FSNUY
Want to see FSNUY full AI Analyst Report?
Top Page
Fresenius SE & Co
(OTC:FSNUY)
Select Model
Select Model
Rating:60Neutral
Price Target:
$11.00
▼(-21.65% Downside)
Action:Reiterated
Date:06/06/26
The score is driven primarily by stabilizing financial performance (improving margins and leverage) and supported by reasonable valuation and dividend yield. These positives are tempered by weak technicals, with the stock in a clear downtrend and negative momentum indicators.
Positive Factors
Diversified healthcare portfolio
Fresenius operates hospitals (Helios), dialysis/related care and a pharmaceuticals/clinical nutrition arm (Kabi). This multi‑segment footprint spreads operational risk, smooths revenue cycles across geographies and payers, and supports recurring service and product demand over time.
Negative Factors
Earnings and cash-flow volatility
Historic swings—including a 2023 loss and variable free cash flow—indicate earnings are cyclical and sensitive to operational or macro shocks. This volatility undermines predictability of dividends and reinvestment capacity, raising execution risk over a 2–6 month horizon and beyond.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified healthcare portfolio
Fresenius operates hospitals (Helios), dialysis/related care and a pharmaceuticals/clinical nutrition arm (Kabi). This multi‑segment footprint spreads operational risk, smooths revenue cycles across geographies and payers, and supports recurring service and product demand over time.
Read all positive factors
Fresenius SE & Co (FSNUY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.12B
Dividend Yield1.97%
Average Volume (3M)1.96K
Price to Earnings (P/E)15.0
Beta (1Y)0.36
Revenue Growth12.57%
EPS Growth276.01%
CountryUS
Employees175,202
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.16
Shares Outstanding2,252,949,200
10 Day Avg. Volume0
30 Day Avg. Volume1,958
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)5.76
Price to Sales (P/S)5.00
P/FCF Ratio95.51
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue1.38
Enterprise Value/Gross Profit5.47
Enterprise Value/Ebitda9.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.03
Revenue Forecast (FY)$27.64B
Fresenius SE & Co Business Overview & Revenue Model
Company Description
Fresenius SE & Co. KGaA operates as a global healthcare provider, delivering a comprehensive suite of products and services across dialysis, hospital management, and outpatient medical care. Its operations are structured across four principal divi...
How the Company Makes Money
Fresenius makes money primarily by delivering healthcare services and selling healthcare products through its operating businesses. A major revenue stream comes from Fresenius Helios, which operates hospitals and outpatient facilities; it generate...
Fresenius SE & Co Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveyed a predominantly positive operational and financial picture: strong organic growth, double-digit core EPS expansion, substantial cash generation, and meaningful deleveraging. Kabi and Biopharma are clear growth engines with upgraded margin ambitions and tangible commercial wins. Helios showed quarterly improvement but requires further structural work to sustain gains once temporary measures (surcharge, year‑end effects) normalize. Key risks include macro/regulatory uncertainty (tariffs, PBM reforms), ongoing price pressure in pharma, competitive dynamics in biosimilars, and near‑term corporate cost increases. On balance, the company demonstrated momentum and strengthened financial flexibility that offset the identified execution and external risks.Positive Updates
Full-Year Organic Revenue and EBIT Achievement
Delivered upgraded FY2025 guidance: 7% organic revenue growth and 6% EBIT growth at constant currency, closing the year on a strong note.
Negative Updates
Macroeconomic and Regulatory Uncertainty
Persistent geopolitical and macro volatility noted (recent U.S. Supreme Court ruling on tariffs, evolving PBM reforms). Management acknowledged guidance cannot fully reflect tariff/regulatory uncertainty; FX spot rates could reduce reported metrics by ~1% if unchanged.
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Organic Revenue and EBIT Achievement
Delivered upgraded FY2025 guidance: 7% organic revenue growth and 6% EBIT growth at constant currency, closing the year on a strong note.
Read all positive updates
Company Guidance
Fresenius guided 2026 group organic revenue growth of 4–7% and Core EPS growth at constant currency of 5–10% (Core EPS defined before special items and excluding FMC), targeting a group EBIT margin of around 11.5%. Segment indications are Kabi mid‑to‑high single‑digit organic growth with an EBIT margin of 16.5–17% (longer‑term structural ambition 17–19%; pharma margin ~20%), and Helios mid‑single‑digit organic growth with an EBIT margin of 10–10.5% (including the 3.25% surcharge for publicly insured patients through end‑Oct 2026 and with a 2.98% DRG inflator in 2026 versus 5.9% in 2025). Financial assumptions include CapEx ~5.5% of revenues (up from 4.4%), a tax rate of 24–25%, interest expense broadly in line with the prior year, an FX headwind of ~‑1% on reported revenue/EBIT/Core EPS at Dec‑31 spot rates, and a commitment to stay within a net debt/EBITDA target corridor of 2.5–3x (net debt/EBITDA at 2.7x).Fresenius SE & Co Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
66
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.07B | 21.97B | 21.83B | 22.30B | 40.84B | 37.52B |
| Gross Profit | 5.82B | 5.47B | 5.38B | 5.06B | 10.72B | 10.31B |
| EBITDA | 3.35B | 3.17B | 3.14B | 2.73B | 3.09B | 6.84B |
| Net Income | 1.47B | 1.21B | 471.00M | -594.00M | 1.37B | 1.82B |
Balance Sheet | ||||||
| Total Assets | 42.41B | 41.38B | 43.55B | 45.28B | 76.42B | 71.96B |
| Cash, Cash Equivalents and Short-Term Investments | 2.06B | 1.58B | 2.05B | 2.56B | 2.35B | 2.75B |
| Total Debt | 11.92B | 11.93B | 13.58B | 15.83B | 27.76B | 27.16B |
| Total Liabilities | 21.93B | 21.62B | 23.26B | 25.63B | 44.20B | 42.67B |
| Stockholders Equity | 19.80B | 19.10B | 19.54B | 19.00B | 20.41B | 19.00B |
Cash Flow | ||||||
| Free Cash Flow | 1.42B | 1.15B | 1.52B | 3.32B | 2.28B | 3.03B |
| Operating Cash Flow | 2.88B | 2.59B | 2.45B | 4.46B | 4.20B | 5.08B |
| Investing Cash Flow | -851.64M | -904.82M | -510.00M | -3.19B | -2.61B | -2.82B |
| Financing Cash Flow | -2.41B | -2.32B | -2.18B | -1.38B | -1.60B | -1.45B |
Fresenius SE & Co Technical Analysis
Neutral
14.04
Price Trends
11.64
Negative
12.79
Negative
13.40
Negative
Market Momentum
-0.11
Negative
53.00
Neutral
97.60
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Neutral. The current price of 14.04 is above the 20-day moving average (MA) of 10.88, above the 50-day MA of 11.64, and above the 200-day MA of 13.40, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 53.00 is Neutral, neither overbought nor oversold. The STOCH value of 97.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FSNUY.
Fresenius SE & Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $8.54B | 5.67 | 20.93% | 0.35% | 10.42% | 33.92% | |
70 Outperform | $13.35B | 17.93 | -133.12% | ― | 6.68% | 2.79% | |
68 Neutral | $14.86B | 8.80 | 40.55% | ― | 4.56% | 27.14% | |
66 Neutral | $12.56B | 12.02 | 7.16% | 3.29% | 7.24% | 67.43% | |
60 Neutral | $25.12B | 15.00 | 7.76% | 1.97% | 12.57% | 276.01% | |
58 Neutral | $83.23B | 12.52 | -123.20% | 0.61% | 6.71% | 29.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
FSNUY
Fresenius SE & Co
11.29
-0.81
-6.66%
DVA
DaVita
207.91
70.97
51.83%
FMS
Fresenius Medical Care
23.59
-2.62
-9.99%
HCA
HCA Healthcare
375.17
0.85
0.23%
THC
Tenet Healthcare
172.57
4.56
2.71%
UHS
Universal Health
141.17
-29.34
-17.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.